B38-derived Anti-SARS-CoV2 RBD mAbs, human & mouse isotypes

Specific SARS-CoV-2 Spike-RBD neutralizing recombinant antibody 

Antibody description

InvivoGen provides Anti-CoV2RBD-c2-hIgG1 and Anti-CoV2RBD-c2-mIgG2a isotypes, derived from the specific SARS-CoV-2 neutralizing recombinant monoclonal antibody (mAb) originally described as 'clone B38' [1]. They feature:

• The variable region from 'clone B38' that specifically targets the Spike receptor-binding domain (S-RBD) of SARS-CoV-2 [1]
• The human IgG1 or mouse IgG2a constant region 

Clone B38 was isolated from a convalescent COVID-19 patient and subsequently, confirmed to specifically neutralize SARS-CoV-2, in vitro, by blocking the interaction between the SARS-CoV-2 S-RBD and the host receptor ACE2 [1].  The interaction between clone B38 and the spike-RBD was further characterized by crystallography, suggesting that the antibody sterically hinders ACE2 binding to SARS-CoV-2 [1].

Early in the pandemic, a previously characterized SARS-CoV neutralizing mAb (CR3022) against the S-RBD was rapidly found to cross-react with SARS-CoV-2 [2]. However, CR3022 does not neutralize SARS-CoV-2 possibly because, unlike clone B38, it does not target the ACE2 binding motif in the RBD [3]. Interestingly, synergistic neutralization ability was observed when clone B38 was used in combination with a different epitope-targeting antibody (clone H4) identified in the same study [1]. This makes them a potentially promising virus-targeting antibody cocktail for therapeutic and/or vaccine purposes.

InvivoGen's Anti-CoV2RBD-c2 mAbs (clone B38) have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography, ensuring lot-to-lot reproducibility. Furthermore, Anti-CoV2RBD-c2-hIgG1 and Anti-CoV2RBD-c2-mIgG2a have been functionally validated by ELISA and/or neutralizing assays (see data below). The absence of bacterial contamination has been confirmed by cellular assays. ​

Of note, InvivoGen also offers Anti-CoV2RBD-c1-hIgG1 and Anti-CoV2RBD-c1-mIgG2a, derived from another SARS-CoV-2 neutralizing mAb (Clone H4) [1]. In-house data suggests that B38 displays better inhibition of HEK-Blue™ hACE2 cellinfection by Spike-pseudotyped lentiviral particles, and clone H4 has greater sensitivity for detection by ELISA. However, depending on your application both mAbs may be suitable for the detection of Spike-RBD and neutralization of SARS-CoV-2 infection.

Applications

• Detecting the presence of SARS-CoV-2 in culture supernatant and/or in serum (ELISA)
• Flow cytometry binding assays
• Developing neutralizing antibody cocktails against SARS-CoV-2

Quality control

• Functionally validated by ELISA using a coated Spike-RBD-His fusion peptide

Read our reviews discussing SARS-CoV-2

References

1. Wu, Y. et al. 2020. A non-competing pair of human neutralizing antibodies block the COVID-19 virus binding to its receptor ACE2. Science 368, 1274-1278.
2. Tian X. et al., 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections. 9(1):382-385.
3. Yuan M. et al., 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. DOI: 10.1126/science.abb7269.